Concepts (310)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Helicobacter Infections | 62 | 2022 | 1110 | 4.320 |
Why?
|
| Helicobacter pylori | 62 | 2022 | 1174 | 4.100 |
Why?
|
| Crohn Disease | 6 | 2023 | 283 | 1.900 |
Why?
|
| Colitis, Ulcerative | 5 | 2023 | 213 | 1.530 |
Why?
|
| Inflammatory Bowel Diseases | 4 | 2023 | 313 | 1.450 |
Why?
|
| Stomach Neoplasms | 5 | 2022 | 496 | 1.340 |
Why?
|
| Antibodies, Bacterial | 16 | 2017 | 401 | 1.320 |
Why?
|
| Abdominal Pain | 7 | 2014 | 314 | 1.000 |
Why?
|
| Prevalence | 28 | 2022 | 2628 | 0.730 |
Why?
|
| Breath Tests | 14 | 2006 | 181 | 0.680 |
Why?
|
| Cross-Sectional Studies | 20 | 2022 | 3731 | 0.620 |
Why?
|
| Immunoglobulin G | 11 | 2017 | 790 | 0.560 |
Why?
|
| Asymptomatic Diseases | 1 | 2017 | 87 | 0.540 |
Why?
|
| Adult | 55 | 2023 | 31674 | 0.520 |
Why?
|
| Seroepidemiologic Studies | 12 | 2017 | 144 | 0.520 |
Why?
|
| Stomach Ulcer | 7 | 2007 | 85 | 0.510 |
Why?
|
| Gastroesophageal Reflux | 3 | 2008 | 316 | 0.500 |
Why?
|
| Male | 65 | 2023 | 65576 | 0.500 |
Why?
|
| Adolescent | 34 | 2022 | 20569 | 0.500 |
Why?
|
| Family | 3 | 2017 | 593 | 0.500 |
Why?
|
| Fissure in Ano | 1 | 2015 | 6 | 0.490 |
Why?
|
| Gastrointestinal Diseases | 6 | 2012 | 353 | 0.480 |
Why?
|
| Female | 63 | 2023 | 71482 | 0.460 |
Why?
|
| Socioeconomic Factors | 18 | 2012 | 908 | 0.440 |
Why?
|
| Gastroscopy | 5 | 2022 | 96 | 0.440 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2014 | 59 | 0.420 |
Why?
|
| Diet | 3 | 2007 | 1169 | 0.420 |
Why?
|
| Urea | 10 | 2002 | 233 | 0.420 |
Why?
|
| Alendronate | 4 | 2001 | 21 | 0.410 |
Why?
|
| Middle Aged | 46 | 2018 | 28977 | 0.400 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 12 | 2017 | 834 | 0.400 |
Why?
|
| Vitamin D Deficiency | 1 | 2014 | 76 | 0.400 |
Why?
|
| Humans | 86 | 2023 | 133331 | 0.390 |
Why?
|
| Child | 35 | 2022 | 25863 | 0.390 |
Why?
|
| Surveys and Questionnaires | 15 | 2014 | 3982 | 0.390 |
Why?
|
| Gastritis | 8 | 2007 | 267 | 0.390 |
Why?
|
| Obesity | 3 | 2017 | 2440 | 0.380 |
Why?
|
| Risk Factors | 20 | 2018 | 10951 | 0.380 |
Why?
|
| Aged | 35 | 2018 | 21497 | 0.370 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2017 | 429 | 0.370 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2014 | 343 | 0.360 |
Why?
|
| Bone Density | 1 | 2014 | 377 | 0.350 |
Why?
|
| Peptic Ulcer | 6 | 2015 | 137 | 0.340 |
Why?
|
| Sex Factors | 8 | 2015 | 1353 | 0.330 |
Why?
|
| Child, Preschool | 23 | 2017 | 14872 | 0.330 |
Why?
|
| Duodenal Ulcer | 6 | 2001 | 109 | 0.320 |
Why?
|
| Incidence | 6 | 2018 | 3394 | 0.310 |
Why?
|
| Age Distribution | 6 | 2018 | 427 | 0.310 |
Why?
|
| Enzyme Inhibitors | 3 | 2007 | 606 | 0.290 |
Why?
|
| Young Adult | 7 | 2018 | 9920 | 0.290 |
Why?
|
| Bhutan | 3 | 2017 | 21 | 0.290 |
Why?
|
| Gastric Mucosa | 7 | 2001 | 400 | 0.290 |
Why?
|
| Aged, 80 and over | 14 | 2017 | 7139 | 0.260 |
Why?
|
| Child Day Care Centers | 3 | 2002 | 27 | 0.260 |
Why?
|
| Texas | 9 | 2018 | 3666 | 0.260 |
Why?
|
| Italy | 6 | 2015 | 125 | 0.250 |
Why?
|
| Life Style | 2 | 2007 | 459 | 0.250 |
Why?
|
| Diseases in Twins | 2 | 1998 | 99 | 0.250 |
Why?
|
| Retrospective Studies | 9 | 2023 | 17568 | 0.250 |
Why?
|
| Amoxicillin | 3 | 1996 | 117 | 0.240 |
Why?
|
| Dyspepsia | 3 | 2015 | 103 | 0.240 |
Why?
|
| Host-Pathogen Interactions | 1 | 2007 | 265 | 0.240 |
Why?
|
| Age Factors | 12 | 2011 | 2956 | 0.220 |
Why?
|
| Prospective Studies | 7 | 2017 | 6582 | 0.220 |
Why?
|
| Bacterial Proteins | 4 | 2015 | 924 | 0.220 |
Why?
|
| Hepatitis A | 2 | 2003 | 32 | 0.220 |
Why?
|
| Bismuth | 3 | 1993 | 74 | 0.210 |
Why?
|
| Hepatitis A Virus, Human | 1 | 2003 | 9 | 0.210 |
Why?
|
| Saliva | 2 | 2002 | 132 | 0.200 |
Why?
|
| Gastrointestinal Agents | 1 | 2023 | 66 | 0.200 |
Why?
|
| Vitamins | 1 | 2023 | 113 | 0.200 |
Why?
|
| Urease | 3 | 2006 | 65 | 0.200 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2011 | 313 | 0.190 |
Why?
|
| Logistic Models | 5 | 2017 | 1864 | 0.190 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2007 | 491 | 0.190 |
Why?
|
| Vitamin D | 1 | 2023 | 180 | 0.190 |
Why?
|
| Time Factors | 8 | 2018 | 6544 | 0.190 |
Why?
|
| Naproxen | 1 | 2001 | 20 | 0.180 |
Why?
|
| Odds Ratio | 4 | 2007 | 1253 | 0.170 |
Why?
|
| Cohort Studies | 8 | 2015 | 5199 | 0.170 |
Why?
|
| Gastrostomy | 1 | 2001 | 92 | 0.170 |
Why?
|
| Recurrence | 5 | 2007 | 1469 | 0.160 |
Why?
|
| Drug Therapy, Combination | 6 | 2000 | 1165 | 0.160 |
Why?
|
| Anti-Ulcer Agents | 2 | 1999 | 102 | 0.160 |
Why?
|
| Proton Pump Inhibitors | 2 | 2007 | 275 | 0.160 |
Why?
|
| Omeprazole | 2 | 1996 | 90 | 0.160 |
Why?
|
| Sensitivity and Specificity | 7 | 2008 | 2142 | 0.150 |
Why?
|
| Minority Groups | 1 | 2001 | 251 | 0.150 |
Why?
|
| Salicylates | 3 | 1993 | 47 | 0.150 |
Why?
|
| Antigens, Bacterial | 3 | 2015 | 312 | 0.150 |
Why?
|
| Infant | 7 | 2023 | 13241 | 0.150 |
Why?
|
| Tetracycline | 3 | 1993 | 73 | 0.150 |
Why?
|
| Organometallic Compounds | 3 | 1993 | 106 | 0.140 |
Why?
|
| Urban Health | 1 | 2018 | 78 | 0.140 |
Why?
|
| Body Mass Index | 3 | 2017 | 1713 | 0.140 |
Why?
|
| Cluster Analysis | 2 | 2017 | 436 | 0.140 |
Why?
|
| Emigration and Immigration | 1 | 2018 | 79 | 0.140 |
Why?
|
| Bahrain | 1 | 2017 | 4 | 0.130 |
Why?
|
| Educational Status | 5 | 2007 | 294 | 0.130 |
Why?
|
| Registries | 3 | 2018 | 1581 | 0.130 |
Why?
|
| Fasting | 2 | 2001 | 308 | 0.130 |
Why?
|
| Carbon Isotopes | 6 | 2002 | 274 | 0.130 |
Why?
|
| Environmental Exposure | 1 | 1998 | 236 | 0.120 |
Why?
|
| Hot Temperature | 1 | 1996 | 145 | 0.120 |
Why?
|
| Beverages | 1 | 1996 | 102 | 0.120 |
Why?
|
| Penicillins | 1 | 1996 | 153 | 0.120 |
Why?
|
| Food Preferences | 1 | 1996 | 118 | 0.120 |
Why?
|
| Emigrants and Immigrants | 1 | 2018 | 155 | 0.120 |
Why?
|
| Geographic Mapping | 1 | 2015 | 15 | 0.120 |
Why?
|
| Hyperlipidemias | 1 | 2017 | 199 | 0.120 |
Why?
|
| Schools | 1 | 2017 | 237 | 0.120 |
Why?
|
| Students | 1 | 2017 | 262 | 0.120 |
Why?
|
| Gastric Emptying | 2 | 2014 | 78 | 0.120 |
Why?
|
| Anti-Bacterial Agents | 5 | 2001 | 2575 | 0.110 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2015 | 82 | 0.110 |
Why?
|
| Metronidazole | 4 | 2001 | 149 | 0.110 |
Why?
|
| Nausea | 1 | 2014 | 87 | 0.110 |
Why?
|
| Social Class | 4 | 2007 | 207 | 0.100 |
Why?
|
| Social Environment | 1 | 1994 | 124 | 0.100 |
Why?
|
| Gastroparesis | 1 | 2014 | 65 | 0.100 |
Why?
|
| Russia | 2 | 2007 | 39 | 0.100 |
Why?
|
| Dental Auxiliaries | 1 | 1992 | 2 | 0.100 |
Why?
|
| Dentists | 1 | 1992 | 7 | 0.100 |
Why?
|
| Japan | 3 | 2003 | 152 | 0.100 |
Why?
|
| Radiation Dosage | 1 | 2013 | 147 | 0.100 |
Why?
|
| Safety-net Providers | 1 | 2013 | 62 | 0.100 |
Why?
|
| Occupational Diseases | 1 | 1992 | 74 | 0.090 |
Why?
|
| Malaysia | 2 | 2012 | 17 | 0.090 |
Why?
|
| Chi-Square Distribution | 4 | 2011 | 593 | 0.090 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2015 | 874 | 0.090 |
Why?
|
| Cephalosporins | 1 | 1992 | 143 | 0.090 |
Why?
|
| Reproducibility of Results | 4 | 2008 | 3041 | 0.090 |
Why?
|
| Follow-Up Studies | 5 | 2007 | 5443 | 0.090 |
Why?
|
| Chronic Disease | 1 | 2015 | 1235 | 0.090 |
Why?
|
| Cross-Over Studies | 3 | 2001 | 332 | 0.080 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2015 | 1420 | 0.080 |
Why?
|
| Sweden | 2 | 2000 | 56 | 0.080 |
Why?
|
| Treatment Outcome | 3 | 2023 | 13103 | 0.080 |
Why?
|
| Sex Distribution | 2 | 2002 | 321 | 0.080 |
Why?
|
| Diabetes Mellitus | 1 | 2017 | 938 | 0.070 |
Why?
|
| Serologic Tests | 2 | 2003 | 128 | 0.070 |
Why?
|
| Stress, Psychological | 1 | 2014 | 601 | 0.070 |
Why?
|
| Carbon Dioxide | 3 | 1999 | 283 | 0.070 |
Why?
|
| Sickness Impact Profile | 1 | 2008 | 39 | 0.070 |
Why?
|
| Hypertension | 1 | 2017 | 1403 | 0.070 |
Why?
|
| Twins, Dizygotic | 2 | 2000 | 47 | 0.070 |
Why?
|
| Africa | 1 | 2007 | 140 | 0.070 |
Why?
|
| United States | 7 | 2015 | 11721 | 0.070 |
Why?
|
| Korea | 2 | 1997 | 33 | 0.070 |
Why?
|
| Biopsy | 4 | 1999 | 1204 | 0.070 |
Why?
|
| Twins, Monozygotic | 2 | 2000 | 128 | 0.070 |
Why?
|
| Risk Reduction Behavior | 1 | 2007 | 151 | 0.060 |
Why?
|
| Feeding Behavior | 1 | 2012 | 728 | 0.060 |
Why?
|
| Education | 1 | 2006 | 111 | 0.060 |
Why?
|
| Severity of Illness Index | 4 | 2014 | 3105 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2012 | 3418 | 0.060 |
Why?
|
| Factor Analysis, Statistical | 1 | 2005 | 233 | 0.050 |
Why?
|
| Czech Republic | 1 | 2003 | 12 | 0.050 |
Why?
|
| Double-Blind Method | 4 | 2000 | 1661 | 0.050 |
Why?
|
| Citric Acid | 2 | 2001 | 38 | 0.050 |
Why?
|
| Water Supply | 1 | 2002 | 27 | 0.050 |
Why?
|
| Hygiene | 1 | 2002 | 26 | 0.050 |
Why?
|
| Neoplasms | 1 | 1997 | 2990 | 0.050 |
Why?
|
| Louisiana | 1 | 2002 | 137 | 0.050 |
Why?
|
| Equipment Design | 2 | 2001 | 604 | 0.050 |
Why?
|
| Comorbidity | 1 | 2007 | 1622 | 0.050 |
Why?
|
| Antitrichomonal Agents | 1 | 2001 | 8 | 0.050 |
Why?
|
| Drug Administration Schedule | 2 | 2000 | 748 | 0.040 |
Why?
|
| Erythema | 1 | 2001 | 29 | 0.040 |
Why?
|
| Etidronic Acid | 1 | 2000 | 10 | 0.040 |
Why?
|
| Psychometrics | 1 | 2005 | 690 | 0.040 |
Why?
|
| Nurse's Role | 1 | 2001 | 41 | 0.040 |
Why?
|
| Cellulitis | 1 | 2001 | 63 | 0.040 |
Why?
|
| Clarithromycin | 1 | 2001 | 120 | 0.040 |
Why?
|
| Wound Infection | 1 | 2001 | 57 | 0.040 |
Why?
|
| Equipment Failure | 1 | 2001 | 133 | 0.040 |
Why?
|
| Calcium Channel Blockers | 1 | 2000 | 116 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2001 | 238 | 0.040 |
Why?
|
| Esophagus | 2 | 1999 | 218 | 0.040 |
Why?
|
| Nuclear Family | 1 | 2000 | 51 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 2001 | 250 | 0.040 |
Why?
|
| Bacteriological Techniques | 1 | 2000 | 88 | 0.040 |
Why?
|
| Patient Selection | 2 | 2001 | 734 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 2 | 1996 | 255 | 0.040 |
Why?
|
| Spouses | 1 | 2000 | 71 | 0.040 |
Why?
|
| Disease Transmission, Infectious | 1 | 2000 | 87 | 0.040 |
Why?
|
| Endoscopes, Gastrointestinal | 1 | 1999 | 7 | 0.040 |
Why?
|
| Breast Feeding | 1 | 2001 | 240 | 0.040 |
Why?
|
| Sialic Acids | 1 | 1999 | 20 | 0.040 |
Why?
|
| Statistics, Nonparametric | 3 | 2011 | 446 | 0.040 |
Why?
|
| Health Behavior | 1 | 2002 | 400 | 0.040 |
Why?
|
| Atrophy | 2 | 1996 | 232 | 0.040 |
Why?
|
| Antibodies | 1 | 2000 | 372 | 0.040 |
Why?
|
| Surgical Instruments | 1 | 1999 | 56 | 0.040 |
Why?
|
| Fiber Optic Technology | 1 | 1999 | 45 | 0.040 |
Why?
|
| Lactose | 1 | 1999 | 56 | 0.040 |
Why?
|
| Longitudinal Studies | 2 | 2000 | 1513 | 0.040 |
Why?
|
| Mental Disorders | 1 | 2006 | 891 | 0.040 |
Why?
|
| Lactoferrin | 1 | 1999 | 78 | 0.040 |
Why?
|
| Physicians, Family | 1 | 1998 | 38 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2001 | 562 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2007 | 3718 | 0.040 |
Why?
|
| Duodenoscopy | 1 | 1997 | 17 | 0.030 |
Why?
|
| Sucrose | 1 | 1997 | 43 | 0.030 |
Why?
|
| Lansoprazole | 1 | 1996 | 27 | 0.030 |
Why?
|
| 2-Pyridinylmethylsulfinylbenzimidazoles | 1 | 1996 | 29 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2001 | 1473 | 0.030 |
Why?
|
| Adjuvants, Immunologic | 1 | 1999 | 391 | 0.030 |
Why?
|
| False Negative Reactions | 1 | 1996 | 83 | 0.030 |
Why?
|
| Alcoholism | 1 | 1999 | 252 | 0.030 |
Why?
|
| Feces | 1 | 2000 | 783 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 1999 | 1714 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2010 | 8630 | 0.030 |
Why?
|
| Orphanages | 1 | 1996 | 7 | 0.030 |
Why?
|
| Residence Characteristics | 1 | 1999 | 289 | 0.030 |
Why?
|
| False Positive Reactions | 1 | 1996 | 140 | 0.030 |
Why?
|
| Housing | 1 | 1996 | 54 | 0.030 |
Why?
|
| Aspirin | 1 | 1997 | 231 | 0.030 |
Why?
|
| Child, Hospitalized | 1 | 1996 | 76 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2000 | 1156 | 0.030 |
Why?
|
| Intestinal Mucosa | 1 | 2000 | 791 | 0.030 |
Why?
|
| Virulence | 1 | 2015 | 278 | 0.030 |
Why?
|
| Gastroenterology | 1 | 1998 | 205 | 0.030 |
Why?
|
| Hepatitis C, Chronic | 1 | 1999 | 371 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2000 | 1973 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2000 | 2288 | 0.030 |
Why?
|
| Child Rearing | 1 | 1994 | 27 | 0.030 |
Why?
|
| Pregnancy | 1 | 2007 | 7599 | 0.030 |
Why?
|
| Radionuclide Imaging | 1 | 2014 | 149 | 0.030 |
Why?
|
| Regression Analysis | 2 | 1992 | 809 | 0.030 |
Why?
|
| Topography, Medical | 1 | 2013 | 6 | 0.030 |
Why?
|
| Crowding | 1 | 2013 | 11 | 0.030 |
Why?
|
| Community-Acquired Infections | 1 | 1996 | 247 | 0.030 |
Why?
|
| Ranitidine | 1 | 1992 | 26 | 0.020 |
Why?
|
| Drinking Water | 1 | 2012 | 17 | 0.020 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 1991 | 40 | 0.020 |
Why?
|
| Mesalamine | 1 | 2011 | 6 | 0.020 |
Why?
|
| Radiography | 1 | 2013 | 824 | 0.020 |
Why?
|
| Failure to Thrive | 1 | 2011 | 93 | 0.020 |
Why?
|
| Campylobacter Infections | 1 | 1990 | 35 | 0.020 |
Why?
|
| Health Status Disparities | 1 | 2013 | 252 | 0.020 |
Why?
|
| Steroids | 1 | 2011 | 211 | 0.020 |
Why?
|
| Aging | 2 | 1998 | 1279 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 1463 | 0.020 |
Why?
|
| Immunologic Factors | 1 | 2011 | 186 | 0.020 |
Why?
|
| Developing Countries | 1 | 1991 | 290 | 0.020 |
Why?
|
| Medicaid | 1 | 2011 | 254 | 0.020 |
Why?
|
| Endoscopy, Gastrointestinal | 2 | 2000 | 225 | 0.020 |
Why?
|
| Eructation | 1 | 2007 | 1 | 0.020 |
Why?
|
| Bronchial Spasm | 1 | 2007 | 3 | 0.020 |
Why?
|
| Laryngitis | 1 | 2007 | 7 | 0.020 |
Why?
|
| Hiccup | 1 | 2007 | 6 | 0.020 |
Why?
|
| Proton Pumps | 1 | 2007 | 10 | 0.020 |
Why?
|
| Hoarseness | 1 | 2007 | 12 | 0.020 |
Why?
|
| Pharyngitis | 1 | 2007 | 34 | 0.020 |
Why?
|
| Sialorrhea | 1 | 2007 | 16 | 0.020 |
Why?
|
| Cough | 1 | 2007 | 96 | 0.020 |
Why?
|
| Biomarkers | 1 | 2015 | 3415 | 0.020 |
Why?
|
| Chest Pain | 1 | 2007 | 132 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 1994 | 3363 | 0.010 |
Why?
|
| Kazakhstan | 1 | 2002 | 8 | 0.010 |
Why?
|
| Hepatitis A Antibodies | 1 | 2002 | 9 | 0.010 |
Why?
|
| Carbon Radioisotopes | 1 | 2001 | 75 | 0.010 |
Why?
|
| Drug Resistance, Microbial | 1 | 2001 | 198 | 0.010 |
Why?
|
| Patient Compliance | 2 | 1995 | 477 | 0.010 |
Why?
|
| Occupations | 1 | 2000 | 20 | 0.010 |
Why?
|
| Reference Standards | 1 | 2001 | 245 | 0.010 |
Why?
|
| Vietnam | 1 | 2000 | 63 | 0.010 |
Why?
|
| Bacterial Outer Membrane Proteins | 1 | 2000 | 116 | 0.010 |
Why?
|
| Esophagoscopy | 1 | 2000 | 163 | 0.010 |
Why?
|
| Pentagastrin | 1 | 1999 | 5 | 0.010 |
Why?
|
| Temperance | 1 | 1999 | 15 | 0.010 |
Why?
|
| Gastric Acidity Determination | 1 | 1999 | 23 | 0.010 |
Why?
|
| Glucans | 1 | 1999 | 15 | 0.010 |
Why?
|
| Hydrolysis | 1 | 1999 | 161 | 0.010 |
Why?
|
| Citrates | 1 | 1999 | 24 | 0.010 |
Why?
|
| Substance Abuse, Intravenous | 1 | 1999 | 42 | 0.010 |
Why?
|
| Liver Function Tests | 1 | 1999 | 104 | 0.010 |
Why?
|
| Colonoscopes | 1 | 1999 | 9 | 0.010 |
Why?
|
| Culture Techniques | 1 | 1999 | 79 | 0.010 |
Why?
|
| Equipment Safety | 1 | 1999 | 35 | 0.010 |
Why?
|
| Ascorbic Acid | 1 | 1999 | 78 | 0.010 |
Why?
|
| Colostrum | 1 | 1999 | 59 | 0.010 |
Why?
|
| Information Services | 1 | 1998 | 22 | 0.010 |
Why?
|
| Reference Values | 1 | 1999 | 724 | 0.010 |
Why?
|
| Sex Characteristics | 1 | 1999 | 335 | 0.010 |
Why?
|
| Cattle | 1 | 1999 | 588 | 0.010 |
Why?
|
| Acute Disease | 1 | 2000 | 1184 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2000 | 1583 | 0.010 |
Why?
|
| Colonoscopy | 1 | 1999 | 233 | 0.010 |
Why?
|
| Administration, Oral | 1 | 1999 | 718 | 0.010 |
Why?
|
| Alcohol Drinking | 1 | 1999 | 362 | 0.010 |
Why?
|
| Biological Transport | 1 | 1997 | 367 | 0.010 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 1996 | 53 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1999 | 1433 | 0.010 |
Why?
|
| Observer Variation | 1 | 1996 | 309 | 0.010 |
Why?
|
| Treatment Failure | 1 | 1995 | 362 | 0.010 |
Why?
|
| Twin Studies as Topic | 1 | 1994 | 14 | 0.010 |
Why?
|
| ROC Curve | 1 | 1996 | 606 | 0.010 |
Why?
|
| Genotype | 1 | 2000 | 2720 | 0.010 |
Why?
|
| Causality | 1 | 1994 | 93 | 0.010 |
Why?
|
| Stomach Diseases | 1 | 1994 | 49 | 0.010 |
Why?
|
| Neutrophils | 1 | 1996 | 362 | 0.010 |
Why?
|
| Arkansas | 1 | 1991 | 58 | 0.010 |
Why?
|
| Epidemiologic Methods | 1 | 1991 | 101 | 0.010 |
Why?
|
| India | 1 | 1991 | 239 | 0.010 |
Why?
|
| Campylobacter | 1 | 1990 | 25 | 0.010 |
Why?
|
| Saudi Arabia | 1 | 1990 | 56 | 0.010 |
Why?
|
| Smoking | 1 | 1990 | 944 | 0.000 |
Why?
|
| Animals | 1 | 1999 | 36217 | 0.000 |
Why?
|